布鲁克推出高性能microflex MALDI-TOF用于蛋白质组学研究

2004年3月8日，Pittcon 2004

Bruker Daltonics Introduces High-Performance Benchtop microflex MALDI-TOF for Proteomics Applications

Pittcon 2004

March 08, 2004 07:00 AM Eastern Standard Time

CHICAGO--(BUSINESS WIRE)--March 8, 2004--

New microflex Significantly Outperforms Other Bench-Top MALDI-TOFs

At the 2004 Pittsburgh Conference in Chicago, Bruker Daltonics Inc., an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), today announced the microflex(TM), a high-performance research-grade bench-top Matrix Assisted Laser Desorption Ionization -Time-of-Flight (MALDI-TOF) mass spectrometer. Due to its unique gridless design of ion source and reflectron, this novel instrument provides superior 15k resolution, as well as excellent mass accuracy and outstanding sensitivity.

The microflex is designed as a compact and affordable bench-top package that is convenient for many life-science laboratories. The microflex operates under our integrated Compass(TM) software environment for easy operation in multi-instrument laboratories, and with the most comprehensive bioinformatics analysis software suite in the industry. It can be applied to expression proteomics, clinical proteomics or functional genomics without compromise in performance.

The microflex benefits from our patented AnchorChip(TM) technology which provides homogeneous, exactly-positioned samples on the MALDI-target for robust and fast automation, as well as a sensitivity boost by up to two orders of magnitude. The new microScout(TM) ion source uses targets plates of exactly one quarter the size of industry-standard microtitre plates (MTP). Therefore, four microScout targets can be processed simultaneously with most MTP-compatible laboratory robots.

Furthermore, the microflex system can be an integral module of either our Proteineer(TM) solution for high-success expression proteomics, or our ClinProt(TM) solution for biomarker discovery and clinical proteomics. ClinProt is an integrated set of tools for peptide and protein biomarker discovery and clinical proteomics research, including automated magnetic bead based sample preparation methods, and ClinProTools(TM) comprehensive analysis, visualization and statistical model building software tools.

For pharmaceutical customers, the microflex system offers software tools to support customers in achieving 21 CFR Part 11 compliance. Bruker Daltonics provides optional IQ, OQ and PV services to FDA-regulated customers.

Dr. Ulrich Giessmann, Vice President of Bruker Daltonics, explains: "With the microflex, we have introduced the first very high performance bench-top MALDI-TOF instrument to the life-science mass spectrometry market. By combining well-proven and new technology with a robust support concept, we have generated a next-generation system that can meet the demands of most life science researchers for no-compromise performance in a compact and easy-to-use system. We believe the microflex will appeal particularly to clinical researchers and pharmaceutical customers. The microflex has the potential to grow the bench-top MALDI-TOF market considerably."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies" reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies" products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.

Contacts

Bruker BioSciences

Michael Willett, 978-663-3660, ext. 1411

Michael.Willett@bruker.com